HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Anterior ischemic optic neuropathy — Clinical Guidelines

Overview

Anterior ischemic optic neuropathy (AION) is a condition characterized by sudden vision loss due to insufficient blood flow to the optic nerve head, often affecting one eye. It predominantly affects older adults and can be categorized into anterior (NAION) and posterior types, with NAION being the most common 1 2 3.

Diagnosis

Clinical Presentation: Sudden, painless unilateral vision loss, often worse in the central visual field (altitudinal hemianopia) 1 2.

Fundus Examination: Optic disc swelling (papilledema) with or without hemorrhages 1 2.

Imaging: MRI or CT scans to rule out other causes like compressive lesions 4.

Visual Field Testing: Confirm visual field defects characteristic of AION 1 2.

Differential Diagnosis: Exclude other causes of optic neuropathy, including demyelinating diseases and giant cell arteritis 1 2.

Management

No Specific Pharmacological Treatment: Currently, no definitive pharmacological treatment exists to reverse vision loss 1 2.

Supportive Care: Management focuses on addressing underlying risk factors such as hypertension, diabetes, and sleep apnea 1 2.

Lifestyle Modifications: Encourage smoking cessation, control blood pressure, and manage systemic conditions 1 2.

Monitoring: Regular follow-up to monitor for progression or complications 1 2.

Special Populations

Comorbidities: Patients with systemic conditions like diabetes, hypertension, and obstructive sleep apnea are at higher risk 1 2.

Interferon Alfa Therapy: Potential association with AION; monitor patients on interferon alfa closely 3.

Semaglutide Use: Emerging concerns suggest a possible link between semaglutide and NAION; heightened vigilance advised in users 1 2.

Key Recommendations

Monitor Patients on Interferon Alfa and Semaglutide: Given the potential association with AION, closely monitor patients on these medications for signs of optic neuropathy (Evidence: Moderate) 3 1.

Control Underlying Risk Factors: Aggressively manage systemic conditions such as hypertension and diabetes to reduce the risk of AION (Evidence: Strong) 1 2.

Regular Follow-Up: Schedule frequent ophthalmologic evaluations for early detection and management of AION progression (Evidence: Expert opinion) 1 2.

References

1 Procacci A, Poluzzi E, De Ponti F, Raschi E. Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?. Obesity research & clinical practice 2025. link 2 Azab M, Pasina L. Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysis. Obesity research & clinical practice 2025. link 3 Fraunfelder FW, Fraunfelder FT. Interferon alfa-associated anterior ischemic optic neuropathy. Ophthalmology 2011. link 4 Arbuthnot JE, Journeaux SF, Clark DI. The Birmingham hip resurfacing procedure: a rare complication. The Journal of arthroplasty 2003. link00206-7)

Anterior ischemic optic neuropathy